TUCSON, Ariz., – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for NGS-based molecular profiling applications, today announced the appointment of Suzanne Hill as Vice President of North American Capital Sales.

In this role, Ms. Hill will be responsible for leading the sales team in the commercialization of the

HTG EdgeSeq system and associated reagents in North America. Ms. Hill brings proven capital sales leadership in life science tools to the HTG business team with an extensive background in sequencing and genomics. Prior to joining HTG, Ms. Hill served as Director of Sales at Silicon Biosystems in San Diego, CA. Earlier in her career, she held a number of commercial positions of increasing responsibility at Illumina, Inc. Prior to her seven years at Illumina, Ms. Hill was the Director of Sales for North Americaat CryoXtract, the Mid Atlantic Regional Sales Manager at Leica, and Regional and Global Account Executive at Perkin Elmer and Roche.

“We are delighted to be able to recruit someone of Suzanne’s background and experience,” stated TJ Johnson, Chief Executive Officer and President of HTG. “Ms. Hill’s genomics sales leadership, especially her seven years at Illumina during their initial commercial ramp up phase, will be extremely helpful as we accelerate the commercialization of HTG’s instrument platform.”

Ms. Hill earned a B.S. in biology and plant genetics from Penn State University.

About HTG:

Headquartered in Tucson, Arizona, HTG’s mission is to empower precision medicine at the local level. In 2013, the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG’s proprietary nuclease protection chemistry. HTG’s product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available atwww.htgmolecular.com.